BlueWillow’s Intranasal Bird Flu Vaccine: A Potential Game-Changer in Influenza Prevention BlueWillow Biologics, Inc., a clinical-stage biotech company at the forefront of intranasal vaccine technology, announced compelling results from a peer‑reviewed Nature Communications study. The research highlights the potential of the company’s intranasal bird flu vaccine to elicit robust mucosal and systemic immune responses, a…